Back to Search Start Over

Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report.

Authors :
Ciolli G
Pasquini A
Mannelli F
Scappini B
Gianfaldoni G
Quinti E
Fasano L
Caroprese J
Crupi F
Vannucchi AM
Piccini M
Source :
Therapeutic advances in hematology [Ther Adv Hematol] 2024 Sep 23; Vol. 15, pp. 20406207241270846. Date of Electronic Publication: 2024 Sep 23 (Print Publication: 2024).
Publication Year :
2024

Abstract

Polyethylene-glycolated Escherichia coli -derived l-asparaginase (pegaspargase, pASP) is an essential component of paediatric-inspired regimens for the treatment of acute lymphoblastic leukaemia/lymphoma; nonetheless, is characterised by severe and potentially life-threatening toxicities, such as hypertriglyceridemia. Grades 3-4 events have been reported in ~1%-18% of paediatric patients and in sparse reports in adults. There is limited evidence on the safety of asparaginase rechallenge in patients experiencing severe pASP-related hypertriglyceridemia. Herein we present the case of a young adult patient diagnosed with T-LBL who experienced an asymptomatic severe pASP-related hypertriglyceridemia and was safely re-exposed to ASP using Erwinia chrysanthemi asparaginase (crisantapase), with only mild transient hypertriglyceridemia recurrence.<br />Competing Interests: The authors declare that there is no conflict of interest.<br /> (© The Author(s), 2024.)

Details

Language :
English
ISSN :
2040-6207
Volume :
15
Database :
MEDLINE
Journal :
Therapeutic advances in hematology
Publication Type :
Academic Journal
Accession number :
39328469
Full Text :
https://doi.org/10.1177/20406207241270846